Neurodegeneration
A £30 million strategic partnership with UK Dementia Research Institute to translate promising discoveries into new treatments and diagnostics.
Alongside our dedicated Motor Neuron Disease Translational Challenge, we’re looking more broadly at research into dementia and neurodegenerative conditions.
Neurodegenerative conditions affect over 1 million people in the UK. As the population ages, that number is rising.
We’re partnering with the UK Dementia Research Institute to support discovery research with our translational expertise.
Our partnership with the UK Dementia Research Institute
We’ve signed a 5-year, £30 million commitment with UK Dementia Research Institute (UK DRI) to support research at 6 host universities in the UK.
Over 800 UK DRI researchers will conduct discovery research into the mechanisms underpinning conditions like Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and vascular dementia.
Our experts will then help to translate these into tests, treatments and devices.
What do we want to achieve?
Listening to those with lived experiences of these conditions, we seek to:
- improve prediction and diagnosis of these conditions
- connect experts across neurodegeneration research
- contribute to development of new medicines, biomarkers and diagnostics
- unblock barriers that keep scientific discoveries from reaching patients
Featured project
NEURii: transforming care for people living with dementia
A two-year collaborative research agreement to fast-track the development of scalable digital solutions that can transform care.
Latest news
-
Two major UK decisions announced on use of Alzheimer’s drug, lecanemab
-
LifeArc appoints new chair for neurodegeneration efforts
-
Seven neurodegeneration research projects receive £14.5m from LifeArc-UKDRI partnership